66 studies found for:    GIST | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy
Condition: Gastrointestinal Stromal Tumor
Intervention:
2 Recruiting Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
Condition: GIST
Intervention: Drug: Vandetanib
3 Unknown  Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST
Conditions: Renal Cell Cancer;   Colorectal Cancer;   GIST
Intervention: Other: Questionnaires
4 Recruiting Detection of CF-DNA in Patients With Gastrointestinal Stromal Tumors (GIST)
Condition: Gastrointestinal Stromal Tumors
Intervention: Other: Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years
5 Recruiting A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: sunitinib malate dose escalation;   Drug: sunitinib malate
6 Recruiting A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
Condition: 3rd Line GIST
Intervention: Drug: ST571 + BYL719
7 Recruiting A Study of AUY922 for GIST(Gastrointestinal Stromal Tumor) Patients
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
8 Not yet recruiting Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)
Conditions: Gastrointestinal Stromal Tumors;   KIT +;   Resected Gastrointestinal Stromal Tumors;   Non-metastatic;   High Risk of Recurrence
Intervention: Drug: Imatinib maintenance
9 Not yet recruiting Ph II CABOGIST in GIST
Condition: Metastatic Gastrointestinal Stromal Tumor
Intervention: Drug: cabozantinib
10 Recruiting Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Advanced Gastrointestinal Stromal Tumors
Intervention: Drug: PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.
11 Unknown  Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Pazopanib
12 Unknown  A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: masitinib (AB1010);   Drug: imatinib
13 Recruiting Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: Sunitinib;   Drug: Regorafenib
14 Recruiting Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
15 Recruiting Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: imatinib mesylate;   Procedure: conventional surgery
16 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
17 Recruiting MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: MEK162;   Drug: Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
18 Recruiting BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Condition: Advanced Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: BGJ398;   Drug: Imatinib Mesylate
19 Not yet recruiting Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence
Condition: Gastro-Intestinal Stromal Tumour
Interventions: Drug: Masitinib;   Drug: Placebo
20 Available Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (BAY73-4506)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years